Replies to post #214050 on Biotech Values

[bladerunner1717]

re: CTMX AMGN

ghmm,

Thanks for your notes on the conference call.

I notice the collaboration includes bi-specific antibodies. There seems to be some skepticism about bi-specific antibodies in the oncology community. Do you view this collaboration as somewhat a validation of the bi-specific antibody technology, in general? Do you think this gives any sort of validation to AFMD's bi-specific antibody technology. (Lindhtu and I seem to be the only ones here interested in AFMD. The stock has seemingly bottomed out.)

Bladerunner